People ask whether Ozempic (semaglutide) causes thyroid cancer because every semaglutide product carries an FDA Boxed Warning — the agency's strongest warning — about a risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). The scary phrase is real and comes from the official FDA prescribing information, which is why searchers encounter it.
The Boxed Warning is built on ANIMAL data: in rodents, semaglutide caused dose- and duration-dependent thyroid C-cell tumors. The FDA label explicitly states it is UNKNOWN whether semaglutide causes thyroid C-cell tumors (including MTC) in humans, because the human relevance of the rodent findings has not been determined. Rodent thyroids have far more C-cells and are more responsive to this drug class than human thyroids. Human causation is therefore NOT established. Human data are limited and genuinely mixed: a French nested case-control study (Bezin, Diabetes Care 2023) found an increased risk after 1-3 years of GLP-1 use (all thyroid cancer adjusted HR 1.58, 95% CI 1.27-1.95; MTC HR 1.78, 95% CI 1.04-3.05), but this can be inflated by detection bias; a larger Scandinavian cohort (Pasternak, BMJ 2024, mean 3.9-yr follow-up) found no substantial increase versus DPP-4 inhibitors (HR 0.93, 95% CI 0.66-1.31). One study points up, the other to no meaningful difference — the science is still open and absolute risk, if any, appears small.
Semaglutide is contraindicated — meaning do not use it — in patients with a personal or family history of medullary thyroid carcinoma (MTC), or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is stated verbatim in the FDA label. Tell your prescriber about any family history of thyroid cancer before starting; for this group it is not a risk/benefit judgment call.
The label directs clinicians to counsel patients on symptoms of a thyroid tumor: a lump, mass, or swelling in the neck; persistent hoarseness; trouble swallowing (dysphagia); and ongoing shortness of breath (dyspnea). Contact a doctor if these develop. Importantly, routine thyroid-cancer screening solely because you take semaglutide is generally NOT recommended — the FDA label states routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early MTC detection in treated patients. Absent symptoms or a personal/family risk history, regular calcitonin tests or neck ultrasounds are not advised just because you started the drug.
The FDA Boxed Warning is real, but it is based on rodent studies; whether semaglutide causes thyroid cancer in humans is not established and the human data are limited and conflicting (one study a modest signal, one no meaningful difference). If you or a close relative has MTC or MEN 2, do not take it — it is contraindicated. For everyone else: know the warning signs, but routine thyroid screening is not recommended solely because you take it. The right move is a conversation with your prescriber about personal and family history — neither fear nor dismissal.
General information, not medical advice. An FDA boxed warning reflects a rodent finding and a precaution, not proof that the drug causes thyroid cancer in people. Discuss your personal and family history with your clinician, and seek care for a neck lump, hoarseness, or trouble swallowing.